Treatment of melanoma patients by adoptive transfer of in vitro manipulated tumor-reactive T cells has yielded dramatic successes, but extending this strategy to the treatment of other malignancies has proven more difficult. This has reflected in part difficulties identifying immunogenic tumor antigens (Ags) that can be safely and effectively targeted, the low avidity of T cells for the identified tumor Ags that are usually also detected in normal tissues, and immuno-suppressive pathways associated with many progressive tumors that interfere with effective immune responses. Advances in the last decade, including molecular profiling of tumors to find candidate target Ags, methods to genetically engineer high avidity T cell responses, and strategies to disrupt immuno-regulatory pathways and modify the tumor microenvironment, have provided opportunities to pursue T cell therapy. WT1 and mesothelin (MSN) are pro-oncogenic proteins over-expressed by many human tumors with limited expression in normal adult tissues that are being evaluated in human cancer vaccine trials. However, only a small fraction of patients have exhibited clinical benefit, with most failig to achieve T cell responses of large magnitude or high avidity. This could be addressed by adoptive T cell therapy with T cells transduced to express a genetically-engineered high affinity TCR. Our lab has isolated TCRs targeting these Ags and developed new strategies to improve the breadth and qualities of high affinity TCRs that can be generated from naturally isolated lower affinity tumor-reactive TCRs, but clinical translation would benefit from analysis in informative preclinical models since T cells with high affinity TCRs may function well as effector cells in vitro but in vivo may mediate injury to normal tissues expressing these Ags, be deleted, and/or lose function. WT1 and MSN expression in normal tissues, as well as in many malignancies, is very similar in mice and humans. Studies in mice that develop spontaneous tumors expressing these Ags, allowing tumor therapy to be evaluated and modulated in the context of a natural tumor microenvironment, can provide needed insights into the function, toxicities and potential efficacy of T cells expressing TCRs with a range of affinities. The overal goals of this project are to assess the potential to enhance therapeutic efficacy without inducing toxicity with T cells expressing TCRs with affinities that can be an order of magnitude greater than clinically to date, and create new TCR immunotherapy reagents that can effectively target tumors not currently treatable.
The specific aims are to: 1) Determine the parameters for engineering TCRs specific for candidate tumor Ags by mutation and positive selection to increase affinity, including changes in on-rates and off-rates, that improve function and therapeutic activity without rendering transduced CD8 T cells toxic to normal tissues;and 2) Determine if adoptive transfer of tumor-reactive T cells expressing high affinity TCRs, can achieve and/or improve therapeutic efficacy, either alone or with reagents modifying the tumor microenvironment, in a murine model of 'spontaneous'pancreas cancer that reproduces most aspects of human disease.

Public Health Relevance

Adoptive T cell therapy of cancer, in which large numbers of patient T cells reactive with tumor cells are generated outside the body and infused back into a patient, has shown substantial promise, but broad application has been in part limited by difficulty generating T cells that can recognize and bind strongly to the tumor cell in each patient. This can be potentially overcome with modern molecular techniques in which the recognition structure, the T cell receptor (TCR), is isolated from the T cell and mutated to achieve much higher affinity for the tumor antigen, and then inserted into large numbers of T cells from the patient to impart specificity and provide a potent response. This project will evaluate the rules governing how much increase in TCR affinity for two candidate human cancer antigens can be achieved to improve antitumor activity without causing toxicity to normal tissues that express low levels of the antigen or interfering with T cell function. This will be studied ina mouse model of spontaneously developing pancreatic cancer that expresses the tumor antigens being targeted and recapitulates the human disease, with the goal of developing a strategy that can be translated not only to the treatment of patients with progressive pancreatic cancer but also other tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA033084-30A1
Application #
8504648
Study Section
Cancer Immunopathology and Immunotherapy Study Section (CII)
Program Officer
Mccarthy, Susan A
Project Start
1982-08-01
Project End
2018-03-31
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
30
Fiscal Year
2013
Total Cost
$552,495
Indirect Cost
$173,376
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Schietinger, Andrea; Philip, Mary; Krisnawan, Varintra E et al. (2016) Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis. Immunity 45:389-401
Stromnes, Ingunn M; Schmitt, Thomas M; Hulbert, Ayaka et al. (2015) T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma. Cancer Cell 28:638-52
Schmitt, Thomas M; Stromnes, Ingunn M; Chapuis, Aude G et al. (2015) New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies. Clin Cancer Res 21:5191-7
Chowell, Diego; Krishna, Sri; Becker, Pablo D et al. (2015) TCR contact residue hydrophobicity is a hallmark of immunogenic CD8+ T cell epitopes. Proc Natl Acad Sci U S A 112:E1754-62
Stromnes, Ingunn M; Greenberg, Philip D; Hingorani, Sunil R (2014) Molecular pathways: myeloid complicity in cancer. Clin Cancer Res 20:5157-70
Stromnes, Ingunn M; Brockenbrough, J Scott; Izeradjene, Kamel et al. (2014) Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut 63:1769-81
Stromnes, Ingunn M; DelGiorno, Kathleen E; Greenberg, Philip D et al. (2014) Stromal reengineering to treat pancreas cancer. Carcinogenesis 35:1451-60
Finton, Kathryn A K; Friend, Della; Jaffe, James et al. (2014) Ontogeny of recognition specificity and functionality for the broadly neutralizing anti-HIV antibody 4E10. PLoS Pathog 10:e1004403
Schietinger, Andrea; Greenberg, Philip D (2014) Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol 35:51-60
Stromnes, Ingunn M; Schmitt, Thomas M; Chapuis, Aude G et al. (2014) Re-adapting T cells for cancer therapy: from mouse models to clinical trials. Immunol Rev 257:145-64

Showing the most recent 10 out of 90 publications